Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes
Language English Country England, Great Britain Media electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27646588
PubMed Central
PMC5028781
DOI
10.1038/srep33379
PII: srep33379
Knihovny.cz E-resources
- MeSH
- Models, Biological MeSH
- Phosphatidylethanolamines MeSH
- Folic Acid metabolism MeSH
- Humans MeSH
- Liposomes * chemistry ultrastructure MeSH
- Metallothionein metabolism MeSH
- Disease Models, Animal MeSH
- Antibodies, Monoclonal administration & dosage MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms drug therapy metabolism pathology MeSH
- Sarcosine antagonists & inhibitors chemistry MeSH
- Tumor Burden drug effects MeSH
- Dose-Response Relationship, Drug MeSH
- Xenograft Model Antitumor Assays MeSH
- Zinc metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- dioleoyl phosphatidylethanolamine MeSH Browser
- Phosphatidylethanolamines MeSH
- Folic Acid MeSH
- Liposomes * MeSH
- Metallothionein MeSH
- Antibodies, Monoclonal MeSH
- Sarcosine MeSH
- Zinc MeSH
Herein, we describe the preparation of liposomes with folate-targeting properties for the encapsulation of anti-sarcosine antibodies (antisarAbs@LIP) and sarcosine (sar@LIP). The competitive inhibitory effects of exogenously added folic acid supported the role of folate targeting in liposome internalization. We examined the effects of repeated administration on mice PC-3 xenografts. Sar@LIP treatment significantly increased tumor volume and weight compared to controls treated with empty liposomes. Moreover, antisarAbs@LIP administration exhibited a mild antitumor effect. We also identified differences in gene expression patterns post-treatment. Furthermore, Sar@LIP treatment resulted in decreased amounts of tumor zinc ions and total metallothioneins. Examination of the spatial distribution across the tumor sections revealed a sarcosine-related decline of the MT1X isoform within the marginal regions but an elevation after antisarAbs@LIP administration. Our exploratory results demonstrate the importance of sarcosine as an oncometabolite in PCa. Moreover, we have shown that sarcosine can be a potential target for anticancer strategies in management of PCa.
See more in PubMed
Siegel R. L., Miller K. D. & Jemal A. Cancer Statistics, 2015. CA-Cancer J. Clin. 65, 5–29 (2015). PubMed
Abate-Shen C. & Shen M. M. Molecular genetics of prostate cancer. Genes Dev. 14, 2410–2434 (2000). PubMed
Sreekumar A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910–914 (2009). PubMed PMC
Cao D. L. et al. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis. 14, 166–172 (2011). PubMed
Cao D. L. et al. A Multiplex Model of Combining Gene-Based, Protein-Based, and Metabolite-Based With Positive and Negative Markers in Urine for the Early Diagnosis of Prostate Cancer. Prostate 71, 700–710 (2011). PubMed
Heger Z. et al. Determination of common urine substances as an assay for improving prostate carcinoma diagnostics. Oncol. Rep. 31, 1846–1854 (2014). PubMed
Lucarelli G. et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0?ng/ml. Prostate 72, 1611–1621 (2012). PubMed
Jentzmik F. et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur. Urol. 58, 12–18 (2010). PubMed
Khan A. P. et al. The Role of Sarcosine Metabolism in Prostate Cancer Progression. Neoplasia 15, 491–501 (2013). PubMed PMC
Cernei N. et al. Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line. Oncol. Rep. 29, 2459–2466 (2013). PubMed
Heger Z. et al. Paramagnetic Nanoparticles as a Platform for FRET-Based Sarcosine Picomolar Detection. Sci Rep 5, 1–7 (2015). PubMed PMC
Leamon C. P. Folate-targeted drug strategies for the treatment of cancer. Curr. Opin. Investig. Drugs 9, 1277–1286 (2008). PubMed
Pollock S. et al. Uptake and trafficking of liposomes to the endoplasmic reticulum. Faseb J. 24, 1866–1878 (2010). PubMed
Heger Z. et al. 17 beta-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line. Oncol. Rep. 33, 921–929 (2015). PubMed
Hattori Y. & Maitani Y. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther. 12, 796–809 (2005). PubMed
Zhao D. M. et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int. J. Nanomed. 5, 669–677 (2010). PubMed PMC
Bahrami B. et al. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumor Biol. 36, 5727–5742 (2015). PubMed
Nelson W. G., De Marzo A. M. & Isaacs W. B. Mechanisms of disease: Prostate cancer. N. Engl. J. Med. 349, 366–381 (2003). PubMed
Chen C. et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature 500, 486–489 (2013). PubMed PMC
Chaudhury A. & Das S. Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs. Curr. Pharm. Biotechnol. 16, 333–343 (2015). PubMed
Sabharanjak S. & Mayor S. Folate receptor endocytosis and trafficking. Adv. Drug Deliv. Rev. 56, 1099–1109 (2004). PubMed
Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. J. Control. Release 164, 138–144 (2012). PubMed
Talmadge J. E., Singh R. K., Fidler I. J. & Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 170, 793–804 (2007). PubMed PMC
Chames P., Van Regenmortel M., Weiss E. & Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220–233 (2009). PubMed PMC
Cernei N. et al. Sarcosine as a Potential Prostate Cancer Biomarker-A Review. Int. J. Mol. Sci. 14, 13893–13908 (2013). PubMed PMC
Trudel D., Fradet Y., Meyer F., Harel F. & Tetu B. Significance of MMP-2 expression in prostate cancer: An immunohistochemical study. Cancer Res. 63, 8511–8515 (2003). PubMed
Peng B. et al. AP-1 Transcription Factors c-FOS and c-JUN Mediate GnRH-Induced Cadherin-11 Expression and Trophoblast Cell Invasion. Endocrinology 156, 2269–2277 (2015). PubMed
Kaukoniemi K. M. et al. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med. 4, 1417–1425 (2015). PubMed PMC
Adams S. J., Aydin I. T. & Celebi J. T. GAB2-a Scaffolding Protein in Cancer. Mol. Cancer Res. 10, 1265–1270 (2012). PubMed PMC
Ding C. B., Yu W. N., Feng J. H. & Luo J. M. Structure and function of Gab2 and its role in cancer (Review). Mol. Med. Rep. 12, 4007–4014 (2015). PubMed PMC
Mignard V., Lalier L., Paris F. & Vallette F. M. Bioactive lipids and the control of Bax pro-apoptotic activity. Cell Death Dis. 5, 1–8 (2014). PubMed PMC
Schmid M. et al. The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: Which markers matter and how should they be used? World J. Urol. 32, 871–880 (2014). PubMed
Tisman G. & Garcia A. Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report. J Med. Case Rep. 5, 413–418 (2011). PubMed PMC
Pan T. J. et al. Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. Biochem. Biophys. Res. Commun. 456, 452–458 (2015). PubMed
Wang Q. et al. Targeting Amino Acid Transport in Metastatic Castration-Resistant Prostate Cancer: Effects on Cell Cycle, Cell Growth, and Tumor Development. JNCI-. Natl. Cancer Inst. 105, 1463–1473 (2013). PubMed
Beauchamp E. M. & Platanias L. C. The evolution of the TOR pathway and its role in cancer. Oncogene 32, 3923–3932 (2013). PubMed
Hasumi M. et al. Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues. Cancer Lett. 200, 187–195 (2003). PubMed
Franklin R. B. et al. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol. Cancer 4, 1–13 (2005). PubMed PMC
Heger Z. et al. Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance? Current Drug Targets In press (2015). PubMed
Vogel C. & Marcotte E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227–232 (2012). PubMed PMC
Leitao R. G. et al. Study of human prostate spheroids treated with zinc using X ray microfluorescence. 2014 Ieee International Symposium on Medical Measurements and Applications (Memea) 599–603 (2014).
Song Y. H., Shiota M., Kuroiwa K., Naito S. & Oda Y. The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod. Pathol. 24, 1272–1280 (2011). PubMed
Bradford M. M. Rapid and sensitive method for quantification of microgram quantities of protein utilizing principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976). PubMed
Heger Z. et al. 3D-printed biosensor with poly(dimethylsiloxane) reservoir for magnetic separation and quantum dots-based immunolabeling of metallothionein. Electrophoresis 36, 1256–1264 (2015). PubMed
Nejdl L. et al. Interaction study of arsenic (III and V) ions with metallothionein gene (MT2A) fragment. Int. J. Biol. Macromol. 72, 599–605 (2015). PubMed
Roth K. M., Peyvan K., Schwarzkopf K. R. & Ghindilis A. Electrochemical detection of short DNA oligomer hybridization using the CombiMatrix ElectraSense Microarray reader. Electroanalysis 18, 1982–1988 (2006).
Kaushal V., Herzog C., Haun R. S. & Kaushal G. P. In Caspases, Paracaspases, and Metacaspases: Methods and Protocols Vol. 1133 Methods in Molecular Biology (eds Bozhkov P. V. & Salvesen G.) 141–154 (Humana Press Inc, 2014).
Casadonte R. & Caprioli R. M. Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Nat. Protoc. 6, 1695–1709 (2011). PubMed PMC
Tmejova K. et al. Structural effects and nanoparticle size are essential for quantum dots-metallothionein complex formation. Colloid Surf. B-Biointerfaces 134, 262–272 (2015). PubMed
Zinc-Modified Nanotransporter of Doxorubicin for Targeted Prostate Cancer Delivery